Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02001623 · ClinicalTrials.gov registry record · Phase 1
Tisotumab Vedotin (HuMax®-TF-ADC) Safety Study in Patients With Solid Tumors
A Phase 1 study, sponsored by Seagen.
- Completed
- Registry status
- Phase 1
- Development phase
- 195
- Enrollment target
NCT02001623: Completed Phase 1 study, sponsored by Seagen.
NCT02001623 is a Phase 1 study that has completed, run by Seagen. The registered enrollment target is 195 participants, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (225% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02001623, a Phase 1 study, has completed, sponsored by Seagen.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 195 participants
- Enrollment target
Study Summary
The purpose of the trial is to establish the tolerability of HuMax-TF-ADC in a mixed population of patients with specified solid tumors.
Primary Outcome
Evaluation of treatment-emergent adverse events (TEAEs) includes number of participants with at least one: TEAE Serious TEAE Infusion-related TEAE Common Terminology Criteria for Adverse Events (CTCAE) grade \>=3 Treatment-related TEAE A CTCAE TEAE was determined using the CTCAE grading systems based on National Cancer Institute (NCI)-CTCAE version 4.03 assessed by the investigator per the below definitions. Grade 3: Severe or medically significant but not immediately life-threatening; hospit
Interventions
- DRUG Tisotumab Vedotin (HuMax-TF-ADC)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 195 participants |
| Start Date | 2013-11-30 |
| Est. Completion | 2019-05-02 |
| Phase | Phase 1 |
What the finished NCT02001623 record still lists
NCT02001623 is an interventional study that assigns participants to a tested intervention. The registered 195 participants enrollment target is mid-sized for trials with a published cap, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (225% higher).
The record links to 0 conditions, and to 1 intervention - of which Tisotumab Vedotin (HuMax-TF-ADC) is the first listed.
NCT02001623 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02001623 about?
NCT02001623 is a clinical study titled "Tisotumab Vedotin (HuMax®-TF-ADC) Safety Study in Patients With Solid Tumors". The purpose of the trial is to establish the tolerability of HuMax-TF-ADC in a mixed population of patients with specified solid tumors.
What is the current status of trial NCT02001623?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 195 participants. The study started on 2013-11-30. Estimated completion is 2019-05-02.
What interventions are being tested in trial NCT02001623?
The interventions under investigation include: Tisotumab Vedotin (HuMax-TF-ADC) (DRUG).
Who is sponsoring clinical trial NCT02001623?
This trial is sponsored by Seagen, which has 84 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02001623's enrollment target sits among peer trials
195 281st of 2000 higher than 1,719 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04276922 · 195 participants · NA
Creative Arts Program to Reduce Burnout in Healthcare Professionals
- NCT04829357 · 195 participants
Post Market Clinical Follow-up Study on TVT ABBREVO® Continence System
- NCT05054738 · 195 participants · NA
CRP and S&A for Inpatient Veterans
- NCT05561595 · 195 participants · NA
Transdiagnostic Intervention to Reduce Internalized Health-Related Stigma
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI